Skip to main content
. Author manuscript; available in PMC: 2025 Oct 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2024 Jun 12;38(5):1011–1025. doi: 10.1016/j.hoc.2024.05.002

Figure 1. Immune checkpoint inhibition unleashes T cell responses and drives T cell- and cytokine-mediated dermatotoxicity.

Figure 1.

CTLA-4 inhibition enhances antigen-specific T cell priming, whereas PD-1 inhibition repositions T cells for antigen access and unlocks their effector potential. CTLA-4 and PD-1 inhibitor treatment causes cutaneous adverse events by mobilizing T cells reactive to self-antigens and commensal bacterial antigens.